Giulia Turri1, Corrado Pedrazzani1, Giovanni Malerba2, Gabriele Gecchele1, Cristian Conti1, Andrea Ruzzenente1, Giuseppe Lippi3, Federica Randon4, Pierluigi Piccoli4, Giorgio Gandini4, Domenico Girelli5, Alfredo Guglielmi1. 1. Department of Surgical Sciences, Dentistry, Gynaecology and Paediatrics, Unit of General and Hepatobiliary Surgery, University of Verona, Verona, Italy. 2. Department of Neurosciences, Biomedicine and Movement, University of Verona, Verona, Italy. 3. Department of Neurological, Biomedical and Movement Sciences, Section of Clinical Biochemistry, University of Verona, Verona, Italy. 4. Department of Transfusion Medicine, Verona University Hospital, Verona, Italy. 5. Department of Medicine, Section of Internal Medicine, University of Verona, Verona, Italy.
Abstract
BACKGROUND: Patients with colorectal cancer often present with anaemia and require red blood cell transfusions (RBCT) during their peri-operative course. Evidence suggests a significant association between RBCT and poor long-term outcomes in surgical patients, but the findings in colorectal cancer are contradictory. MATERIAL AND METHODS: The aim of this retrospective, single-centre, cohort study was to investigate the prognostic role of peri-operative RBCT in a large cohort of patients with stage I-III colorectal cancer submitted to curative surgery between 2005 and 2017. The propensity score matching technique was applied to adjust for potential confounding factors. RESULTS: Among 1,414 patients operated within the study period, 895 fulfilled the inclusion criteria: 29.6% (n=265) received peri-operative RBCT. The group that received peri-operative RBCT was significantly older (p<0.001), had more comorbidities (p<0.001), more advanced tumours (p<0.001) and more colon tumours (p=0.002) and stayed in hospital longer (p<0.001). Post-operative mortality was 7-fold higher (2.3 vs 0.3%, p=0.01) in this group. Survival outcomes were significantly worse in the group receiving RBCT than in the group not receiving RBCT for both overall (64.5 vs 80.1%, p<0.001) and cancer-specific survival (74.3 vs 85.1%, p<0.001). On multivariable analysis, peri-operative RBCT was significantly associated with poorer overall survival (hazard ratio 1.51, p=0.009). When transfused and non-transfused cases were paired through the propensity score matching technique considering main clinico-pathological features, no differences in overall and cancer-specific survival were found. DISCUSSION: Our data suggest that, after adjustment for potential confounding factors, no significant association exists between RBCT and prognosis in colorectal cancer.
BACKGROUND: Patients with colorectal cancer often present with anaemia and require red blood cell transfusions (RBCT) during their peri-operative course. Evidence suggests a significant association between RBCT and poor long-term outcomes in surgical patients, but the findings in colorectal cancer are contradictory. MATERIAL AND METHODS: The aim of this retrospective, single-centre, cohort study was to investigate the prognostic role of peri-operative RBCT in a large cohort of patients with stage I-III colorectal cancer submitted to curative surgery between 2005 and 2017. The propensity score matching technique was applied to adjust for potential confounding factors. RESULTS: Among 1,414 patients operated within the study period, 895 fulfilled the inclusion criteria: 29.6% (n=265) received peri-operative RBCT. The group that received peri-operative RBCT was significantly older (p<0.001), had more comorbidities (p<0.001), more advanced tumours (p<0.001) and more colon tumours (p=0.002) and stayed in hospital longer (p<0.001). Post-operative mortality was 7-fold higher (2.3 vs 0.3%, p=0.01) in this group. Survival outcomes were significantly worse in the group receiving RBCT than in the group not receiving RBCT for both overall (64.5 vs 80.1%, p<0.001) and cancer-specific survival (74.3 vs 85.1%, p<0.001). On multivariable analysis, peri-operative RBCT was significantly associated with poorer overall survival (hazard ratio 1.51, p=0.009). When transfused and non-transfused cases were paired through the propensity score matching technique considering main clinico-pathological features, no differences in overall and cancer-specific survival were found. DISCUSSION: Our data suggest that, after adjustment for potential confounding factors, no significant association exists between RBCT and prognosis in colorectal cancer.
Authors: Ramzi Amri; Anne M Dinaux; Lieve G J Leijssen; Hiroko Kunitake; Liliana G Bordeianou; David L Berger Journal: Surgery Date: 2017-06-09 Impact factor: 3.982
Authors: Christos Perisanidis; Martina Mittlböck; Markus Dettke; Christian Schopper; Alexandra Schoppmann; George C Kostakis; Günter Russmüller; Anton Stift; Anastasios Kanatas; Rudolf Seemann; Rolf Ewers Journal: J Oral Maxillofac Surg Date: 2012-12-21 Impact factor: 1.895
Authors: Michael J Wilson; Ankie W M M Koopman-van Gemert; Joris J Harlaar; Johannes Jeekel; Jaap Jan Zwaginga; Martin Schipperus Journal: Transfusion Date: 2018-09-10 Impact factor: 3.157
Authors: Stephen T McSorley; Alexander Tham; Ross D Dolan; Colin W Steele; Jason Ramsingh; Campbell Roxburgh; Paul G Horgan; Donald C McMillan Journal: Ann Surg Oncol Date: 2019-10-29 Impact factor: 5.344
Authors: Scherwin Mahmoudi; Simon S Martin; Jörg Ackermann; Yauheniya Zhdanovich; Ina Koch; Thomas J Vogl; Moritz H Albrecht; Lukas Lenga; Simon Bernatz Journal: BMC Med Imaging Date: 2021-08-12 Impact factor: 1.930